MDS-MSCs possess increased clonal hematopoiesis-supportive capacities due to a decreased expression of cell surface molecules, including CD44 and CD49e (α5-integrin), and lower or absent expression levels of costimulatory molecules (such as CD40, CD80, and CD86) [128,159,160,161]. The gene discussed is CD44; the disease is myelodysplastic syndrome.